Safety and Efficacy of Non-Pharmacological RIC in Tumor-Bearing Models

Article Impact Level: HIGH
Data Quality: STRONG
Summary of  Basic Research in Cardiology. https://doi.org/10.1007/s00395-026-01160-1  
Dr. Anabel Díaz-Guerra  et al.

Points

Researchers found that remote ischemic conditioning protects the heart from anthracycline damage by using brief interruptions of limb blood flow to activate the body’s natural cardiovascular defense mechanisms.
The study utilized a tumor-bearing mouse model to prove that applying remote ischemic conditioning does not reduce the antitumor effectiveness of doxorubicin or encourage further growth of cancerous cells.
Results from longitudinal echocardiography showed that the non-invasive procedure successfully preserved left ventricular ejection fraction and helped to prevent the cardiac atrophy typically caused by high-dose chemotherapy treatments.
Animals treated with both doxorubicin and remote ischemic conditioning showed a positive trend toward improved overall survival compared to those receiving the chemotherapy medication without any cardiovascular protection.
These preclinical findings support the ongoing RESILIENCE clinical trial which aims to determine if this simple and low-cost technique can reduce heart failure rates among human cancer survivors.

Summary

This study evaluated the efficacy and safety of remote ischemic conditioning (RIC) as a non-pharmacological strategy to prevent anthracycline-induced cardiotoxicity (AIC) without compromising oncological outcomes. Using a tumor-bearing CD1 mouse model, researchers administered five weekly intraperitoneal injections of doxorubicin at a dosage of 5 mg/kg. The primary objective was to determine if the cardioprotective stimulus of RIC—comprised of three cycles of five-minute hindlimb ischemia and reperfusion—would inadvertently protect malignant tissues from the cytotoxic effects of chemotherapy.

Hemodynamic and structural assessments via longitudinal echocardiography revealed that doxorubicin monotherapy induced significant left ventricular (LV) systolic dysfunction and cardiac atrophy. In contrast, the cohort receiving concurrent RIC maintained a preserved left ventricular ejection fraction (LVEF) and exhibited a partial attenuation of early LV atrophy. Furthermore, the RIC group demonstrated a trend toward improved overall survival compared to the doxorubicin-only group, suggesting that the systemic protective mechanisms activated by RIC specifically benefit myocardial homeostasis under chemotherapeutic stress.

Crucially, the study confirmed that RIC does not impair the antitumor efficacy of anthracyclines. Tumor suppression remained comparable between the doxorubicin and doxorubicin plus RIC groups, with no evidence of accelerated tumor growth or reduced cytotoxicity. These findings provide robust preclinical support for the ongoing RESILIENCE clinical trial, suggesting that RIC is a safe, low-cost intervention capable of reducing long-term heart failure risk in cancer survivors without reducing the curative potential of their primary anticancer treatment.

Link to the article: https://link.springer.com/article/10.1007/s00395-026-01160-1

References

Díaz-Guerra, A., Clemente-Moragón, A., Pollán, Á., López-Palomar, L., Cádiz, L., & Ibáñez, B. (2026). Remote ischemic conditioning protects against anthracycline cardiotoxicity without impairing its antitumor activity. Basic Research in Cardiology. https://doi.org/10.1007/s00395-026-01160-1